LRC-TriCEPS™ Publications
Glycomics and Proteomics Approaches to Investigate Early Adenovirus–Host Cell Interactions
Lisa Lasswitz, Naresh Chandra, Niklas Arnberg, Gisa Gerold
jmb Journal of Molecular Biology, doi.org/10.1016/j.jmb.2018.04.039
Received 15 February 2018, Revised 24 April 2018, Accepted 30 April 2018, Available online 7 May 2018.
Adenoviruses as most viruses rely on glycan and protein interactions to attach to and enter susceptible host cells. The Adenoviridae family comprises more than 80 human types and they differ in their attachment factor and receptor usage, which likely contributes to the diverse tropism of the different types. In the past years, methods to systematically identify glycan and protein interactions have advanced. In particular sensitivity, speed and coverage of mass spectrometric analyses allow for high-throughput identification of glycans and peptides separated by liquid chromatography. Also, developments in glycan microarray technologies have led to targeted, high-throughput screening and identification of glycan-based receptors. The mapping of cell surface interactions of the diverse adenovirus types has implications for cell, tissue, and species tropism as well as drug development. Here we review known adenovirus interactions with glycan- and protein-based receptors, as well as glycomics and proteomics strategies to identify yet elusive virus receptors and attachment factors. We finally discuss challenges, bottlenecks, and future research directions in the field of non-enveloped virus entry into host cells.
Keywords
Abbreviations
- Lisa Lasswitz1Naresh Chandra2,3Niklas Arnberg2,3Gisa Gerold1,2,4
- 1 Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, 30625 Hannover, Germany
- 2 Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
- 3 Molecular Infection Medicine Sweden (MIMS), Umeå University, SE-90185 Umea, Sweden
- 4 Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, SE-90185 Umea, Sweden
HATRIC-based identification of receptors for orphan ligands
Nadine Sobotzki, Michael A. Schafroth, Alina Rudnicka, Anika Koetemann, Florian Marty, Sandra Goetze, Yohei Yamauchi, Erick M. Carreira & Bernd Wollscheid
Nature Communications, volume 9, Article number: 1519 (2018) doi:10.1038/s41467-018-03936-z
Published online:
Cellular responses depend on the interactions of extracellular ligands, such as nutrients, growth factors, or drugs, with specific cell-surface receptors. The sensitivity of these interactions to non-physiological conditions, however, makes them challenging to study using in vitro assays. Here we present HATRIC-based ligand receptor capture (HATRIC-LRC), a chemoproteomic technology that successfully identifies target receptors for orphan ligands on living cells ranging from small molecules to intact viruses. HATRIC-LRC combines a click chemistry-based, protein-centric workflow with a water-soluble catalyst to capture ligand-receptor interactions at physiological pH from as few as 1 million cells. We show HATRIC-LRC utility for general antibody target validation within the native nanoscale organization of the surfaceome, as well as receptor identification for a small molecule ligand. HATRIC-LRC further enables the identification of complex extracellular interactomes, such as the host receptor panel for influenza A virus (IAV), the causative agent of the common flu.
Nadine Sobotzki, Michael A. Schafroth, Alina Rudnicka, Anika Koetemann, Florian Marty, Sandra Goetze, Yohei Yamauchi, Erick M. Carreira & Bernd Wollscheid
Staphylococcal Superantigens Use LAMA2 as a Coreceptor GPCT signaling To Activate T Cells
Zhigang Li, Joseph J. Zeppa, Mark A. Hancock, John K. McCormick, Terence M. Doherty, Geoffrey N. Hendy and Joaquín Madrenas
J Immunol January 15, 2018, ji1701212; DOI: https://doi.org/10.4049/jimmunol.1701212 (Published online February 5, 2018)
This work was supported by the Canadian Institutes for Health Research. J.M. holds a tier I Canada Research Chair in Human Immunology. The Department of Microbiology and Immunology Flow Cytometry and Cell Sorting Facility and McGill Surface Plasmon Resonance–Mass Spectrometry Facility are supported by the Canada Foundation for Innovation.
Canonical Ag-dependent TCR signaling relies on activation of the src-family tyrosine kinase LCK. However, staphylococcal superantigens can trigger TCR signaling by activating an alternative pathway that is independent of LCK and utilizes a Gα11-containing G protein–coupled receptor (GPCR) leading to PLCβ activation. The molecules linking the superantigen to GPCR signaling are unknown. Using the ligand-receptor capture technology LRC-TriCEPS, we identified LAMA2, the α2 subunit of the extracellular matrix protein laminin, as the coreceptor for staphylococcal superantigens. Complementary binding assays (ELISA, pull-downs, and surface plasmon resonance) provided direct evidence of the interaction between staphylococcal enterotoxin E and LAMA2. Through its G4 domain, LAMA2 mediated the LCK-independent T cell activation by these toxins. Such a coreceptor role of LAMA2 involved a GPCR of the calcium-sensing receptor type because the selective antagonist NPS 2143 inhibited superantigen-induced T cell activation in vitro and delayed the effects of toxic shock syndrome in vivo. Collectively, our data identify LAMA2 as a target of antagonists of staphylococcal superantigens to treat toxic shock syndrome.
Zhigang Li, Joseph J. Zeppa, Mark A. Hancock, John K. McCormick, Terence M. Doherty, Geoffrey N. Hendy and Joaquín Madrenas
Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma
Authors: Karina Galoian, Silva Abrahamyan, Gor Chailyan, Amir Qureshi, Parthik Patel, Gil Metser, Alexandra Moran, Inesa Sahakyan, Narine Tumasyan, Albert Lee, Tigran Davtyan, Samvel Chailyan and Armen Galoyan
Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed.
Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed. We have previously reported that mTORC1 inhibitor, antitumorigenic cytostatic proline rich polypeptide 1 (PRP-1), galarmin caused a significant upregulation of tumor suppressors including TET1/2 and SOCS3 (known to be involved in inflammatory processes), downregulation of oncoproteins and embryonic stem cell marker miR-302C and its targets Nanog, c-Myc and Bmi-1 in human chondrosarcoma. To understand better the mechanism of PRP-1 action it was very important to identify the receptor it binds to. Nuclear pathway receptor and GPCR assays indicated that PRP-1 receptors are not G protein coupled, neither do they belong to family of nuclear or orphan receptors. In the present study, we have demonstrated that PRP-1 binding interacting partners belong to innate immunity pattern recognition toll like receptors TLR1/2 and TLR6 and gel forming secreted mucin MUC5B. MUC5B was identified as PRP-1 receptor in human chondrosarcoma JJ012 cell line using Ligand-receptor capture technology. Toll like receptors TLR1/2 and TLR6 were identified as binding interaction partners with PRP-1 by western blot analysis in human chondrosarcoma JJ012 cell line lysates. Immunocytochemistry experiments confirmed the finding and indicated the localization of PRP-1 receptors in the tumor nucleus predominantly. TLR1/2, TLR6 and MUC5B were downregulated in human chondrosarcoma and upregulated in dose-response manner upon PRP-1 treatment. Experimental data indicated that in this cellular context the mentioned receptors had tumor suppressive function.
- Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma
- Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1
- Restoration of desmosomal junction protein expression and inhibition of H3K9‑specific histone demethylase activity by cytostatic proline‑rich polypeptide‑1 leads to suppression of tumorigenic potential in human chondrosarcoma cells
- Analysis of IL6‑protein complexes in chondrosarcoma
- Epigenetic control of cancer by neuropeptides (Review)
Karina Galoian, Silva Abrahamyan, Gor Chailyan, Amir Qureshi, Parthik Patel, Gil Metser, Alexandra Moran, Inesa Sahakyan, Narine Tumasyan, Albert Lee, Tigran Davtyan, Samvel Chailyan and Armen Galoyan
Identification of Putative Receptors for the Novel Adipokine CTRP3 Using Ligand-Receptor Capture Technology
PLoS One. 2016 Oct 11;11(10):e0164593. doi: 10.1371/journal.pone.0164593. eCollection 2016.
Li Y1, Ozment T2, Wright GL1, Peterson JM1,3.
We used Ligand-receptor glycocapture technology with TriCEPS™-based ligand-receptor capture (LRC-TriCEPS; Dualsystems Biotech AG). The LRC-TriCEPS experiment with CTRP3-FLAG protein as ligand and insulin as a control ligand was performed on the H4IIE rat hepatoma cell line.
Initial analysis demonstrated efficient coupling of TriCEPS to CTRP3. Further, flow cytometry analysis (FACS) demonstrated successful oxidation and crosslinking of CTRP3-TriCEPS and Insulin-TriCEPS complexes to cell surface glycans. Demonstrating the utility of TriCEPS under these conditions, the insulin receptor was identified in the control dataset. In the CTRP3 treated cells a total enrichment of 261 peptides was observed. From these experiments 5 putative receptors for CTRP3 were identified with two reaching statistically significance: Lysosomal-associated membrane protein 1 (LAMP-1) and Lysosome membrane protein 2 (LIMP II). Follow-up Co-immunoprecipitation analysis confirmed the association between LAMP1 and CTRP3 and further testing using a polyclonal antibody to block potential binding sites of LAMP1 prevented CTRP3 binding to the cells.
The LRC-TriCEPS methodology was successful in identifying potential novel receptors for CTRP3.
The identification of the receptors for CTRP3 are important prerequisites for the development of small molecule drug candidates, of which none currently exist, for the treatment NAFLD.
Li Y1, Ozment T2, Wright GL1, Peterson JM1,3.
- 1Quillen College of Medicine, Department of Biomedical Sciences, East Tennessee State University, Johnson City, Tennessee, United States of America.
- 2Quillen College of Medicine, Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee, United States of America.
- 3College of Public Health, Department of Health Sciences, East Tennessee State University, Johnson City, Tennessee, United States of America.
Serum stimulation of CCR7 chemotaxis due to coagulation factor XIIa-dependent production of high-molecular-weight kininogen domain 5
Current Issue – vol. 113 no. 45 – Manish P. Ponda, E7059–E7068, doi: 10.1073/pnas.1615671113
Contributed by Jan L. Breslow, September 23, 2016 (sent for review August 1, 2016; reviewed by Myron Cybulsky and Carl F. Nathan)
Manish P. Pondaa and Jan L. Breslowa,1
Chemokines and their receptors play a critical role in immune function by directing cell-specific movement. C-C chemokine receptor 7 (CCR7) facilitates entry of T cells into lymph nodes. CCR7-dependent chemotaxis requires either of the cognate ligands C-C chemokine ligand 19 (CCL19) or CCL21. Although CCR7-dependent chemotaxis can be augmented through receptor up-regulation or by increased chemokine concentrations, we found that chemotaxis is also markedly enhanced by serum in vitro.
To identify potential receptors in an unbiased manner, we used ligand–receptor capture (LRC-TriCEPS) technology as a tool for detecting T-lymphocyte surface proteins that physically interact with H497–K520 (Fig. 5A) (20). Transferrin was used as a control ligand to eliminate nonspecific interactions with the TriCEPS reagent.
TriCEPS Ligand-Receptor Capture.
The TriCEPS reagent is a proprietary trifunctional molecule with three key moieties: (i) an amine-reactive group capable of binding a peptide ligand of interest, (ii) a cross-linking group capable of bonding to oxidized glycans, and (iii) an affinity tag for downstream extraction (20, 50). These studies were performed by DualSystems Biotech. Briefly, either human H497–K520 or transferrin was coupled to the TriCEPS reagent. The TriCEPS–ligand complex was added to CCRF-CEM cells in complete medium in the presence or absence of zinc (100 μM), after treatment with an oxidizing reagent to oxidize surface glycoproteins. Cells were then lysed and processed as described, including LC-MS/MS analysis of captured peptides (20). Comparisons between conditions were made in triplicate to determine the relative fold enrichment of a given protein. P values were determined for pairwise comparisons and adjusted for multiple comparisons.
aLaboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York, NY 10065
aLaboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York, NY 10065
Laminin targeting of a peripheral nerve-highlighting peptide enables degenerated nerve visualization
Current Issue – vol. 113 no. 45- Heather L. Glasgow, 12774–12779, doi: 10.1073/pnas.161164211
Contributed by Roger Y. Tsien, August 3, 2016 (sent for review November 16, 2015; reviewed by Joshua E. Elias and Jeff W. Lichtman)
Heather L. Glasgowa,1, Michael A. Whitneya, Larry A. Grossb, Beth Friedmana, Stephen R. Adamsa, Jessica L. Crispb, Timon Hussainc, Andreas P. Freid, Karel Novyd, Bernd Wollscheidd, Quyen T. Nguyenc, and Roger Y. Tsiena,b,e,2
Target-blind activity-based screening of molecular libraries is often used to develop first-generation compounds, but subsequent target identification is rate-limiting to developing improved agents with higher specific affinity and lower off-target binding. A fluorescently labeled nerve-binding peptide, NP41, selected by phage display, highlights peripheral nerves in vivo. Nerve highlighting has the potential to improve surgical outcomes by facilitating intraoperative nerve identification, reducing accidental nerve transection, and facilitating repair of damaged nerves. To enable screening of molecular target-specific molecules for higher nerve contrast and to identify potential toxicities, NP41’s binding target was sought. Laminin-421 and -211 were identified by proximity-based labeling using singlet oxygen and by an adapted version of TRICEPS-based ligand-receptor capture to identify glycoprotein receptors via ligand cross-linking. In proximity labeling, photooxidation of a ligand-conjugated singlet oxygen generator is coupled to chemical labeling of locally oxidized residues. Photooxidation of methylene blue–NP41-bound nerves, followed by biotin hydrazide labeling and purification, resulted in light-induced enrichment of laminin subunits α4 and α2, nidogen 1, and decorin (FDR-adjusted P value < 10−7) and minor enrichment of laminin-γ1 and collagens I and VI. Glycoprotein receptor capture also identified laminin-α4 and -γ1. Laminins colocalized with NP41 within nerve sheath, particularly perineurium, where laminin-421 is predominant. Binding assays with phage expressing NP41 confirmed binding to purified laminin-421, laminin-211, and laminin-α4. Affinity for these extracellular matrix proteins explains the striking ability of NP41 to highlight degenerated nerve “ghosts” months posttransection that are invisible to the unaided eye but retain hollow laminin-rich tubular structures.
aDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093;
aDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093;
bHoward Hughes Medical Institute, University of California, San Diego, La Jolla, CA 92093;
aDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093;
aDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093;
bHoward Hughes Medical Institute, University of California, San Diego, La Jolla, CA 92093;
cDivision of Otolaryngology–Head and Neck Surgery, University of California, San Diego, La Jolla, CA 92093;
dInstitute of Molecular Systems Biology at the Department of Health Sciences and Technology, CH-8093 Zurich, Switzerland;
dInstitute of Molecular Systems Biology at the Department of Health Sciences and Technology, CH-8093 Zurich, Switzerland;
dInstitute of Molecular Systems Biology at the Department of Health Sciences and Technology, CH-8093 Zurich, Switzerland;
cDivision of Otolaryngology–Head and Neck Surgery, University of California, San Diego, La Jolla, CA 92093;
aDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093;
bHoward Hughes Medical Institute, University of California, San Diego, La Jolla, CA 92093;
eDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093
Identification of cell surface receptors for the novel adipokine CTRP3
April 2016, The FASEB Journal, vol. 30 no. 1 Supplement 1249.2
C1q TNF Related Protein 3 (CTRP3) is a member of a family of secreted proteins that exert a multitude of biological effects throughout the body. Our initial work shows promise in the development of CTRP3-induced cellular processes as a means to combat nonalcoholic fatty liver disease (NAFLD). Clinically, NAFLD is defined as the excessive accumulation of fat in the liver, usually due to obesity, and NAFLD effects 1 in 10 Americans. Our previous data show that when high fat fed mice are treated with CTRP3 they are protected from developing NAFLD. However, the mechanism for this effect remains unclear. The purpose of this project was to identify the unknown receptor that mediates the hepatic actions of CTRP3. .
We used Ligand-receptor glycocapture technology with TriCEPS™-based ligand-receptor capture (LRC-TriCEPS; Dualsystems Biotech AG). The LRC-TriCEPS experiment with CTRP3-FLAG protein as ligand and Insulin as the control ligand was performed on H4IIE rat hepatoma cell line. Additional analysis using siRNA induced knockdown of the identified receptors was used to validate the findings.
Initial analysis demonstrated efficient coupling of TriCEPS to CTRP3. Further, flow cytometry analysis demonstrated successful oxidation and crosslinking of CTRP3-TriCEPS and Insulin-TriCEPS to the cell surface glycans. In total, an enrichment of glycopeptides of 11% (261 peptides) was observed. Under these conditions, INSR (Insulin receptor) could be identified and quantified in the control dataset. For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur.
The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.
The identification of the receptors for CTRP3 are important prerequisites for the development of small molecule drug candidates, of which none currently exist, for the treatment NAFLD.
Health Sciences, East Tennessee State University, Johnson City, TN
This abstract is from the Experimental Biology 2016 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Dilp8 requires the neuronal relaxin receptor Lgr3 to couple growth to developmental timing
Nature Communications 6, Article number: 8732 (2015), doi:10.1038/ncomms9732
- Received:
- Accepted:
- Published online:
Andres Garelli, Fabiana Heredia, Andreia P. Casimiro, Andre Macedo, Catarina Nunes, Marcia Garcez, Angela R. Mantas Dias, Yanel A. Volonte, Thomas Uhlmann, Esther Caparros, Takashi Koyama & Alisson M. Gontijo
How different organs in the body sense growth perturbations in distant tissues to coordinate their size during development is poorly understood. Here we mutate an invertebrate orphan relaxin receptor gene, the Drosophila Leucine-rich repeat-containing G protein-coupled receptor 3 (Lgr3), and find body asymmetries similar to those found in insulin-like peptide 8 (dilp8) mutants, which fail to coordinate growth with developmental timing. Indeed, mutation or RNA intereference (RNAi) against Lgr3 suppresses the delay in pupariation induced by imaginal disc growth perturbation or ectopic Dilp8 expression. By tagging endogenous Lgr3 and performing cell type-specific RNAi, we map this Lgr3 activity to a new subset of CNS neurons, four of which are a pair of bilateral pars intercerebralis Lgr3-positive (PIL) neurons that respond specifically to ectopic Dilp8 by increasing cAMP-dependent signalling. Our work sheds new light on the function and evolution of relaxin receptors and reveals a novel neuroendocrine circuit responsive to growth aberrations.
Phenotypic screening—the fast track to novel antibody discovery
ScienceDirekt, doi.org/10.1016/j.ddtec.2017.03.004
Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK
Available online 25 April 2017
Section editors: Neil O Carragher – Institute of Genetics and Molecular Medicine, Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, United Kingdom. Jonathan A. Lee – Quantitative Biology, Eli Lilly and Company, Indianapolis, Indiana. Ellen L. Berg – BioMAP Systems Division of DiscoverX, DiscoverX Corporation.
The majority of antibody therapeutics have been isolated from target-led drug discovery, where many years of target research preceded drug program initiation. However, as the search for validated targets becomes more challenging and target space becomes increasingly competitive, alternative strategies, such as phenotypic drug discovery, are gaining favour. This review highlights successful examples of antibody phenotypic screens that have led to clinical drug candidates. We also review the requirements for performing an effective antibody phenotypic screen, including antibody enrichment and target identification strategies. Finally, the future impact of phenotypic drug discovery on antibody drug pipelines will be discussed.
A Mass Spectrometric-Derived Cell Surface Protein Atlas
Published: April 20, 2015 – http://dx.doi.org/10.1371/journal.pone.0121314
Cell surface proteins are major targets of biomedical research due to their utility as cellular markers and their extracellular accessibility for pharmacological intervention. However, information about the cell surface protein repertoire (the surfaceome) of individual cells is only sparsely available. Here, we applied the Cell Surface Capture (CSC) technology to 41 human and 31 mouse cell types to generate a mass-spectrometry derived Cell Surface Protein Atlas (CSPA) providing cellular surfaceome snapshots at high resolution. The CSPA is presented in form of an easy-to-navigate interactive database, a downloadable data matrix and with tools for targeted surfaceome rediscovery (http://wlab.ethz.ch/cspa).
The cellular surfaceome snapshots of different cell types, including cancer cells, resulted in a combined dataset of 1492 human and 1296 mouse cell surface glycoproteins, providing experimental evidence for their cell surface expression on different cell types, including 136 G-protein coupled receptors and 75 membrane receptor tyrosine-protein kinases. Integrated analysis of the CSPA reveals that the concerted biological function of individual cell types is mainly guided by quantitative rather than qualitative surfaceome differences. The CSPA will be useful for the evaluation of drug targets, for the improved classification of cell types and for a better understanding of the surfaceome and its concerted biological functions in complex signaling microenvironments.
Damaris Bausch-Fluck
Affiliations Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland, Department of Health Sciences and Technology, BMPP, ETH Zurich, Zurich, Switzerland
Andreas Hofmann
Current Address: Novartis Institute of Biomedical Research, Novartis, Basel, Switzerland
Affiliation Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
Thomas Bock
Current Address: European Molecular Biology Laboratory, Heidelberg, Germany
Affiliation Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
Andreas P. Frei
Current Address: Department of Microbiology and Immunology, Stanford School of Medicine, Stanford, California, United States of America
Affiliation Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
Ferdinando Cerciello
Current Address: James Thoracic Center, James Cancer Center, The Ohio State University Medical Center, Columbus, Ohio, United States of America
Affiliations Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland, Laboratory of Molecular Oncology, University Hospital Zurich, Zurich, Switzerland
Andrea Jacobs
Current Address: Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland
Affiliation Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
Hansjoerg Moest
Current Address: Novartis Institute of Biomedical Research, Novartis, Basel, Switzerland
Affiliation Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
Ulrich Omasits
Affiliations Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland, Department of Health Sciences and Technology, BMPP, ETH Zurich, Zurich, Switzerland
Rebekah L. Gundry
Affiliation Department of Biochemistry, Medical College of Wisconsin, Wisconsin, Milwaukee, United States of America
Charles Yoon
Affiliation Institute for Biomaterials & Biomedical Engineering, University of Toronto, Toronto, Canada
Ralph Schiess
Current Address: ProteoMediX AG, Schlieren, Switzerland
Affiliation Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
Alexander Schmidt
Current Address: Proteomics Core Facility, Biozentrum, University of Basel, Basel, Switzerland
Affiliation Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
Paulina Mirkowska
Affiliations Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland, Oncology Research Laboratory, University Children Hospital Zurich, Zurich, Switzerland
Anetta Härtlová
Current Address: College of Life Sciences, University of Dundee, Dundee, United Kingdom
Affiliation Centre of Advanced Studies, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic
Jennifer E. Van Eyk
Current Address: Cedars-Sinai, Clinical Biosystem Research Institute, Los Angeles, California, United States of America
Affiliation Department of Medicine, Biological Chemistry and Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
Jean-Pierre Bourquin
Affiliation Oncology Research Laboratory, University Children Hospital Zurich, Zurich, Switzerland
Ruedi Aebersold
Affiliations Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland, Center for Systems Physiology and Metabolic Diseases, Zurich, Switzerland, Faculty of Science, University of Zurich, Zurich, Switzerland
Kenneth R. Boheler
Affiliations SCRMC, LKS Faculty of Medicine, Hong Kong University, Hong Kong, Hong Kong SAR, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
Peter Zandstra
Affiliation Institute for Biomaterials & Biomedical Engineering, University of Toronto, Toronto, Canada
Bernd Wollscheid
* E-mail: wbernd@ethz.ch
Affiliations Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland, Department of Health Sciences and Technology, BMPP, ETH Zurich, Zurich, Switzerland
Competing Interests
The authors have declared that no competing interests exist.
Author Contributions
Conceived and designed the experiments: DBF BW KRB PZ RA. Performed the experiments: DBF AH TB APF FC AJ HM RLG CY RS AS PM AH. Analyzed the data: DBF UO. Contributed reagents/materials/analysis tools: AS APF FC TB BW. Wrote the paper: DBF BW. Supervised experiments: JVE JPB.
Direct identification of ligand-receptor interactions on living cells and tissues
Nature Biotechnology 30, 997–1001 doi:10.1038/nbt.2354 – ReceivedAcceptedPublished online
Many cellular responses are triggered by proteins, drugs or pathogens binding to cell-surface receptors, but it can be challenging to identify which receptors are bound by a given ligand. Here we describe TRICEPS, a chemoproteomic reagent with three moieties—one that binds ligands containing an amino group, a second that binds glycosylated receptors on living cells and a biotin tag for purifying the receptor peptides for identification by quantitative mass spectrometry. We validated this ligand-based, receptor-capture (LRC) technology using insulin, transferrin, apelin, epidermal growth factor, the therapeutic antibody trastuzumab and two DARPins targeting ErbB2. In some cases, we could also determine the approximate ligand-binding sites on the receptors. Using TRICEPS to label intact mature vaccinia viruses, we identified the cell surface proteins AXL, M6PR, DAG1, CSPG4 and CDH13 as binding factors on human cells. This technology enables the identification of receptors for many types of ligands under near-physiological conditions and without the need for genetic manipulations.
Ligand-based receptor identification on living cells and tissues using TRICEPS
Affiliations ¦ Contributions ¦Corresponding authors
Nature Protocols 8, 1321–1336 (2013) doi:10.1038/nprot.2013.072
- Published online 13 June 2013
Physiological responses to ligands such as peptides, proteins, pharmaceutical drugs or whole pathogens are generally mediated through interactions with specific cell surface protein receptors. Here we describe the application of TRICEPS, a specifically designed chemoproteomic reagent that can be coupled to a ligand of interest for the subsequent ligand-based capture of corresponding receptors on living cells and tissues. This is achieved by three orthogonal functionalities in TRICEPS—one that enables conjugation to an amino group containing ligands, a second for the ligand-based capture of glycosylated receptors on gently oxidized living cells and a biotin tag for purifying receptor peptides for analysis by quantitative mass spectrometry (MS). Specific receptors for the ligand of interest are identified through quantitative comparison of the identified peptides with a sample generated by a control probe with known (e.g., insulin) or no binding preferences (e.g., TRICEPS quenched with glycine). In combination with powerful statistical models, this ligand-based receptor capture (LRC) technology enables the unbiased and sensitive identification of one or several specific receptors for a given ligand under near-physiological conditions and without the need for genetic manipulations. LRC has been designed for applications with proteins but can easily be adapted for ligands ranging from peptides to intact viruses. In experiments with small ligands that bind to receptors with comparatively large extracellular domains, LRC can also reveal approximate ligand-binding sites owing to the defined spacer length of TRICEPS. Provided that sufficient quantities of the ligand and target cells are available, LRC can be carried out within 1 week.
Discovering ligand-receptor interactions
Affiliations ¦ Corresponding authors
Nature Biotechnology 30, 959–961 (2012) doi:10.1038/nbt.2373
- Published online 10 October 2012
- A new probe identifies cell-surface receptors bound by known ligands.
The power of TRICEPS
Flex your TRICEPS
Nature Chemical Biology 8, 950 (2012) doi:10.1038/nchembio.1126
Published online 26 November 2012
Identifying ligands for receptors in live cells can provide valuable information, providing insight into signaling pathways as well as drug targets, but these interactions can be difficult to detect and quantify. Frei et al. now report a trifunctional chemoproteomic reagent called TRICEPS that binds glycosylated receptors on live cells and allows for the purification of the ligand-receptor complex and identification of receptor-derived peptides by MS. TRICEPS contains three functional groups: an N-hydroxysuccinimide ester for ligand conjugation, a protein….
Protter
Protter — the open-source tool for visualization of proteoforms and interactive integration of annotated and predicted sequence features together with experimental proteomic evidence.
The ability to integrate and visualize experimental proteomic evidence in the context of rich protein feature annotations represents an unmet need of the proteomics community. Protter, a web-based tool that supports interactive protein data analysis and hypothesis generation by visualizing both annotated sequence features and experimental proteomic data in the context of protein topology. Protter supports numerous proteomic file formats and automatically integrates a variety of reference protein annotation sources, which can be readily extended via modular plug-ins. A built-in export function produces publication-quality customized protein illustrations, also for large datasets. Visualizations of surfaceome datasets show the specific utility of Protter both for the integrated visual analysis of membrane proteins and peptide selection for targeted proteomics.
Publication list from 2014 – Previous stopped Services
- Roth, Susanne, S. et al. Nature Immunology 538–545 10.1038/ni.2888
- Agarwal, Vinayak, Vgarwal et al. Nature Chemical Biology 640–647 10.1038/nchembio.1564
- Chen, Jingjing, J. et. al., Journal Cell Biology 523-539 10.1083/jcb.201307043
- Kellner, Nikola, N. et al., PLoS Genetics 10.1371/journal.pgen.1004046
- Barajas, Daniel, D. et al., PLoS Pathog. 10.1371/journal.ppat.1004087
- Kovalev, Nikolay, N. et al., PLoS Pathog. 10.1371/journal.ppat.1004051
- Huo, Yan, Y. et al., PLoS Pathog. 10.1371/journal.ppat.1003949
- Ottoz, Diana S M, DS. et al., Nucleic Acids Research. 10.1093/nar/gku616
- Denay, Grégoire, G. et al., Development 10.1242/dev.103531
- He, Xue, X. et al. Plant Journal 10.1111/tpj.12449
- Schneider, Anja, A. et al., Plant Journal 10.1111/tpj.12474
- Vain, Thomas, T. et al., Plant Physiology 10.1104/pp.114.241216
- Wolff, Natascha A, NA. et al. FASEB Journal 10.1096/fj.13-240564
- Rühle, Thilo, T. et al., Plant Physiology 10.1104/pp.114.237883
- Garcia-Gutierrez, Pablo, P. et al. Journal of Cell. Science 10.1242/jcs.147462
- Law, Bernard M H, BM. et al., Journal of Biology Chemistry 10.1074/jbc.M113.507913
- Chen, Hongyan, H. et al., Journal of Virology 10.1128/JVI.03466-13
- Jia, Dongsheng, D. et al., Journal of Virology 10.1128/JVI.01261-14
- Michielse, C B, CB. et al., Molecular Microbiology 10.1111/mmi.12472
- Wu, Wei, W. et al., PLoS ONE 10.1371/journal.pone.0088636
- Vilardi, Fabio, F. et al., PLoS ONE 10.1371/journal.pone.0085033
- John, Florian, F. et al., PLoS ONE 10.1371/journal.pone.0086862
- Dutta, Siddhartha, S. et al., PLoS ONE 10.1371/journal.pone.0095026
- Luxton, Hayley J, HJ. et al., Molecular Oncology 10.1016/j.molonc.2014.01.009
- Sun, Xiaoli, X. et al., Plant Molecular Biology. 10.1007/s11103-013-0167-4
- Philipp, Matthias, M. et al., BMC Plant Biology 10.1186/1471-2229-14-109
- Karim, Sazzad, S. et al., Plant Molecular Biology 10.1007/s11103-013-0161-x
- Zhang, Kai-Liang, KL. et al., Molecular Cancer 10.1186/1476-4598-13-63
- Nakamura, Yasuyuki, Y. et al. Biotechnology and Bioengineering 10.1002/bit.25125
- Xu, Shuhua, S. et al., American Journal of Physiology Gastrointestinal an Liver Physiology 10.1152/ajpgi.00138.2013
- Ortiz-Román, Luisa, L. et al., Veterinary Microbiology 10.1016/j.vetmic.2014.05.005
- Choi, Suzy, S. et al., Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2014.02.033
- Kittanakom, Saranya, S. et al. Biochemical and Biophysical Research Communications 10.1016/j.bbrc.2014.02.033
- Rai, Jay, J. et al., Molecular Biotechnology 10.1007/s12033-014-9778-5
- Li, Xiaojie, X. et al., Arabidopsis J. Biosci (PDF)
- Bahieldin, Ahmed, A. et al., Plasmid 10.1016/j.plasmid.2014.03.001
- Seo, Kyoung-Won, KW. et al., Cell Biology International. 10.1002/cbin.10186
- Jung, Woo-Sung, WS. et al., Cell Biology International 10.1002/cbin.10306
- Gunter, Amanda AB. et al., Thesis
- Ramírez Ríos, Sacnicte, S. et al., Biochimica et Biophysica Acta (BBA) – Bioenergetics Pages 1271–1283 10.1016/j.bbabio.2014.03.020
- Cvrčková, Fatima, F. et al., Methods in Molecular Biology pp 267-282 10.1007/978-1-62703-643-6_23
- Tanaka, Shigeyuki, S. et al., Elife (Cambridge) 10.7554/eLife.01355
- Mar, ThiThi, T. et al., Journal of Proteomics Pages 83–97 10.1016/j.jprot.2014.03.004
- Amrane, Samir, S. et al., Biomolecular NMR Assignments pp 109-112 10.1007/s12104-013-9463-9
- Brandão, Rogelio, RL. et al., Journal of Mycology (PDF)
- Gu, Chunsun, C. et al., Scientific Report Article number: 5833 10.1038/srep05833
- Potschin, Maren. et al., Journal of Plant Growth Regulation pp 106-118
CaptiVate Services
- Freed et al., PLOS Genet. (2012) 8(8):e1002892
- Schaeuble et al., J. Cell Sci. (2012) 125:4463
- Glatter et al. Molecular Systems Biology 5:237 (2009)
- Application note: Analysis of the human phosphatase system PP2A read more (155 KB)
- Larsen, Dorthe H, DH et al. Nature Cell Biology 792–803 10.1038/ncb3007
